March 6, 2019 08:03 AM ESTUpdated 10:57 AM
Deals

As op­po­si­tion mounts against Cel­gene deal, Bris­tol-My­ers tells share­hold­ers the planned buy­out is the best bet in a scarce mar­ket

Natalie Grover

Reporter

Fac­ing bru­tal op­po­si­tion against its planned $74 bil­lion ac­qui­si­tion of Cel­gene, Bris­tol-My­ers Squibb is now scram­bling to con­vince share­hold­ers that its takeover of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times